Engineering the Next Generation of CAR T Therapy:
Dual target strategy; in vivo innovation
Pipeline
Tempest is a clinical-stage CAR-T company building the future of in vivo CAR-T therapy with broad potential benefit for patients with autoimmune diseases or cancer
News
September 23,
2026
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
September 15,
2026
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 11,
2026
Tempest Therapeutics Announces Up to $7.5 Million Private Placement